SCA Pharmaceuticals, LLC — FDA Warning Letter, 2026-09-14: CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Here's the summary: The FDA Center for Drug Evaluation and Research issued Warning Letter WL #724202 on September 14, 2026, to SCA Pharmaceuticals, LLC (8821 Knoedl Court, Little Rock, AR), a registered outsourcing facility under section 503B of the FDCA, following an inspection from October 20-30, 2025. The FDA identified serious CGMP deficiencies in sterile drug production, including inadequate ISO 5 area certification, poor aseptic technique by technicians and assistants that compromised unidirectional airflow, insufficient component controls allowing foreign material on syringe stoppers, inadequate microbial contamination response procedures, and incomplete environmental monitoring—resulting in drug products (including Fentanyl Citrate, Bupivacaine HCl, and Methadone HCl lots cited) that violate the FDCA as adulterated drugs prepared under insanitary conditions.
Argus analysis
# FDA Warning Letter Analysis: SCA Pharmaceuticals, LLC
**Company and Findings**
SCA Pharmaceuticals, LLC, a registered outsourcing facility in Little Rock, Arkansas, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on September 14, 2026, following an inspection conducted October 20–30, 2025. FDA determined that the facility produced sterile drug products—including Fentanyl Citrate, Bupivacaine HCl, and Methadone HCl formulations—under insanitary conditions that violated current good manufacturing practice (CGMP) requirements, potentially rendering products adulterated and harmful to patients.
**Regulatory Citations and Meaning**
The violations center on 21 CFR 211.42, 211.113, 211.160, 211.192, and 211.22, which establish baseline manufacturing standards for sterile drugs. Specifically, FDA cited failures in: ISO 5 cleanroom certification and airflow visualization studies under dynamic conditions; inadequate environmental monitoring placement during aseptic operations; personnel practices that disrupted unidirectional airflow (leaning into hoods, blocking first-pass air); insufficient component controls allowing foreign material on syringe stoppers; and deficient corrective action protocols following microbial contamination detection. Additionally, the facility failed to retain production video recordings—critical quality documentation—before overwriting occurred, preventing root-cause analysis of contamination events.
**Next Steps and Industry Watchpoints**
SCA Pharmaceuticals received FDA Form FDA 483 on October 30, 2025, and submitted responses November 21 and December 31, 2025. The warning letter does not specify a response deadline, though compliance officers should anticipate FDA may issue import alerts, product recalls, or enforcement actions if corrective measures prove inadequate. Peer facilities should monitor whether SCA achieves reinspection clearance or faces facility closure, and whether affected lot numbers trigger recalls. This letter underscores FDA's heightened focus on aseptic processing controls and documentation retention in outsourcing facilities.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER SCA Pharmaceuticals, LLC MARCS-CMS 724202 — September 14, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Recipient Name Kenneth P. Bonnell Recipient Title Chief Quality Officer SCA Pharmaceuticals, LLC 8821 Knoedl Court Little Rock , AR 72205-4600 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER WL # 724202 September 14, 2026 Dear Mr. Bonnell: You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b] 1 on December 13, 2013, and most recently on December 5, 2025. From October 20, 2025, to October 30, 2025, an FDA investigator inspected your facility, SCA Pharmaceuticals, LLC located at 8821 Knoedl Court, Little Rock, Arkansas 72205. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk. FDA issued a Form FDA 483 to your facility on October 30, 2025. We reviewed your November 21, 2025, and December 31, 2025, responses to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA. A. Compounded Drug Products under the FDCA Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met. An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211. B. Violations of the FDCA Adulterated Drug Products The FDA investigator collected evidence indicating that drug products intended or expecte…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to SCA Pharmaceuticals, LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). SCA Pharmaceuticals, LLC — FDA Warning Letter, 2026-09-14: CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-sca-pharmaceuticals-llc-2026-09-14-cgmp
"SCA Pharmaceuticals, LLC — FDA Warning Letter, 2026-09-14: CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-sca-pharmaceuticals-llc-2026-09-14-cgmp.
Argus HQ Research. "SCA Pharmaceuticals, LLC — FDA Warning Letter, 2026-09-14: CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed October 15, 2026. https://argushq.ai/fda/warning-letter/fda-wl-sca-pharmaceuticals-llc-2026-09-14-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_sca_pharmaceuticals_llc_2026_09_14_cgmp_2026,
title = {SCA Pharmaceuticals, LLC — FDA Warning Letter, 2026-09-14: CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-sca-pharmaceuticals-llc-2026-09-14-cgmp},
note = {Accessed: October 15, 2026}
}